Theratechnologies Inc.TSX: TH

Theratechnologies reports on a positive meeting with Health Canada for its ThGRF Phase III program

· Issued by Theratechnologies Inc. via CNW
MONTREAL, May 4 /CNW Telbec/ - Theratechnologies (TSX: TH) reports on a
positive meeting with the Therapeutic Products Directorate (TPD) of Health
Canada held on May 3, 2005, in Ottawa for its Phase III program for ThGRF
(TH9507) in HIV-associated lipodystrophy. Following this meeting, the Company
is now preparing a Phase III Clinical Trial Application (CTA), which will be
submitted to the Canadian regulatory body in the coming weeks. The response
from the TPD is expected within 30 days of receipt of this application.
"We received the go ahead for our Phase III program from the Food and
Drug Administration (FDA) in the United States in late March. Following this
positive meeting with Health Canada, we foresee no major hurdles that would
prevent us from proceeding with our program also in Canada," said Yves
Rosconi, President and Chief Executive Officer of the Company. "All elements
of our Phase III program are coming together as planned and we are on track to
enrol the first patient by mid-year," Mr. Rosconi concluded.

Attractive market opportunity

HIV-associated lipodystrophy is a metabolic syndrome that afflicts a
large percentage of HIV patients undergoing antiretroviral therapy. It is
characterized by changes in distribution of adipose tissue (fat-containing
tissue), dyslipidemia and glucose intolerance. The changes in fat distribution
include visceral fat accumulation and/or the loss of subcutaneous fat,
generally in the limbs and facial area.
There is currently no approved treatment for HIV-associated
lipodystrophy, and although some new HIV treatments have shown signs of
improving metabolic components of the disease, the accumulation of visceral
fat, and the related complications, remains an important unmet medical need.
It is estimated that, among the 1.4 million HIV-positive patients in North
America and Europe, some 200,000 suffer from HIV-associated lipodystrophy with
excess visceral fat. The Company estimates that this could translate into a
market of several hundred million dollars.

About ThGRF

ThGRF is a stabilized analogue of the growth hormone-releasing factor
(GRF) that induces the production and secretion of growth hormone in a
specific, physiological, controlled and pulsatile fashion. This property makes
it a strong candidate as a potential treatment for many diseases related to
aging and obesity, as these conditions are characterized by a significant
reduction in growth hormone secretion.

About Theratechnologies

Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (Phase III) targets HIV-associated lipodystrophy. Other clinical
programs target wasting associated with chronic disease and type 2 diabetes.

This press release contains forward-looking statements regarding the
clinical development of ThGRF and its future commercialization in the
indications described above. Such statements inherently involve numerous risks
and uncertainties, including the success and timely completion of clinical
trials, the ability of the Company to take advantage of the business
opportunities in the biopharmaceutical industry, the granting of the necessary
authorizations, and the general economic conditions. The Company, however, is
not obligated to update this information and does not intend to do so.
Investors are cautioned against placing undue importance on forward-looking
information contained herein and should consult the Company's 2004 Annual
Report, which contains a more exhaustive analysis of risks and uncertainties
connected to the businesses of the Company.

Theratechnologies Inc. on 6ix

Earlier from Theratechnologies

Later from Theratechnologies

All Theratechnologies news releases